REQUEST A DEMO
Total
USD $0.00
Search more companies

Adimmune Corporation (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Adimmune Corporation Profile Updated: July 04, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Founded in 22nd December 1965, Adimmune Corporation principally engages in R&D, manufacture and sale of vaccines and medicines. Production base is in Tanzi, Taichun. The important well-known product is H1N1 vaccine. IPO issued in Forth January 2010. Our main product is the influenza vaccine. The main product of this company, influenza vaccine, is provided to public in Taiwan by Sanofi-Aventis, Novartis and Glaxo Smith Kline (GSK). Major raw materials are the liquid, syringes, and mice. At present, source of supply is stable. Main supplier is Kitasato Institute, the American Royal will and so on. The main sales target is the Department of Health Disease Control in Executive Ministry.

Headquarters
No.3, Sec. 1, Tanxing Rd., Tanzi Township
Taichung City; Taichung City;

Contact Details: Purchase the Adimmune Corporation report to view the information.

Website: http://www.adimmune.com.tw

Basic Information
Total Employees:
Purchase the Adimmune Corporation report to view the information.
Outstanding Shares:
Purchase the Adimmune Corporation report to view the information.
Financial Auditors:
Purchase the Adimmune Corporation report to view the information.
Incorporation Date:
December 22, 1965
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Operating Officer
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
11.31%
Purchase this report to view the information.
3.93%
Purchase this report to view the information.
0.86%
Purchase this report to view the information.
0.7%
Purchase this report to view the information.
0.38%
Subsidiaries
Adimmune B.V (Netherlands)
100%
晉康生命科技有限公司
100%
艾格司農業科技有限公司
100%
Company Performance
Financial values in the chart are available after Adimmune Corporation report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-50.97%
Total operating revenue
-48.89%
Operating profit (EBIT)
4.47%
EBITDA
9.46%
Net Profit (Loss) for the Period
5.34%
Total assets
-5.31%
Total equity
-10.82%
Operating Profit Margin (ROS)
-202.29%
Net Profit Margin
-198.49%
Return on Equity (ROE)
-0.55%
Debt to Equity Ratio
7.93%
Quick Ratio
-0.99%
Cash Ratio
-0.67%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?